Comprehensive study investigates hepatitis B, C, and D prevalence in high-risk groups, highlighting needed targeted intervention.
OBJECTIVES: Comprehensive studies on hepatitis B, C and D virus (HBV, HCV and HDV) infections in high-risk groups are lacking in Africa. This study investigated viral markers among nine high-risk populations in three locations of Burkina Faso. METHODS: Socio-demographic and clinical data, as well as blood samples, were collected from sex workers, men who have sex with men, prisoners, health care workers, lorry drivers, illegal gold miners, hairdressers, haemodialysis patients and human immunodeficiency virus patients. Serum samples were screened using serological and molecular tests; detected viruses were sequenced. RESULTS: Overall, 1373 participants were enrolled. HBsAg seroprevalence was 13.5% and anti-HBc seroprevalence was 75.5%. Among HBsAg-positive samples, HBeAg, anti-HBe and HBV DNA were detected in 18.3%, 79.4% and 30.1% respectively. Total anti-HDV antibodies were detected in 4 (2.1%) samples and HDV RNA in 3 (75.0%). Anti-HCV prevalence was 8.5% and HCV RNA was detected in 13.7%. HBV/HCV coinfection was found in 4 (0.3%) cases. Virus characterization identified genotype 1 for HDV, genotypes A and E for HBV, genotypes 1 and 2 for HCV. CONCLUSIONS: The results showed higher prevalences of HBV and HCV infections than in the general population. They underline the need of targeted programs for these high-risk groups to support the 2030 hepatitis elimination goals.
No takes yet. Share an insight, caveat, or question.
Sanou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: